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Bronchial epithelial cellAirway epithelium is a regulator of innate immune responses to a variety of insults including cigarette smoke.
Cigarette smoke alters the expression and the activation of Toll Like Receptor 4 (TLR4), an innate immunity
receptor. IL-33, an alarmin, increases innate immunity Th2 responses. The aims of this study were to explore
whether mini-bronchoalveolar lavage (mini-BAL) or sera from smokers have altered concentrations of IL-33
and whether cigarette smoke extracts (CSE) alter both intracellular expression (mRNA and protein) and release
of IL-33 in bronchial epithelial cells. The role of TLR4 in the expression of IL-33 was also explored.
Mini-BALs, but not sera, from smokers show reduced concentrations of IL-33. The expression of IL-33 was
increased also in bronchial epithelium from smokers. 20% CSE reduced IL-33 release but increased the mRNA
for IL-33 by real time PCR and the intracellular expression of IL-33 in bronchial epithelial cells as conﬁrmed by
ﬂow cytometry, immunocytochemistry and western blot analysis. The effect of CSE on IL-33 expression was
also observed in primary bronchial epithelial cells. IL-33 expression was mainly concentrated within the
cytoplasm of the cells. LPS, an agonist of TLR4, reduced IL-33 expression, and an inhibitor of TLR4 increased the
intracellular expression of IL-33. In conclusion, the release of IL-33 is tightly controlled and, in smokers, an altered
activation of TLR4 may lead to an increased intracellular expression of IL-33 with a limited IL-33 release.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Lung epithelial cells, which are positioned at the site ofﬁrst exposure
to manymicrobial pathogens and harmful inhaled substances including
cigarette smoke, regulate both innate and adaptive immunity [1].
Prolonged and/or strong epithelial activation can promote the develop-
ment of airway inﬂammatory diseases via the release of large quantities
of pro-inﬂammatory cytokines, growth factors, and chemokines that
attract inﬂammatory cells into the airways.
IL-33 is a cytokine belonging to the IL-1 family (IL-1α, IL-1β, IL-18)
with a dual function, acting both as a traditional cytokine through
activation of the ST2L receptor complex and as an intrace\llular nuclearonoclonal antibody; CM, com-
unologiaMolecolare, Consiglio
lermo, Italy. Tel.: +39 091 680factor with transcriptional regulatory properties [2]. IL-33may be pres-
ent in a full length and in a mature form and increases innate immunity
Th2 responses. IL-33 is increased in patients with pulmonary diseases,
and full-length IL-33 is the predominant form in the lungs in health
and disease [3]. IL-33 is increased in the bronchial epithelium [4] and
in airway smooth muscle cells of asthmatics [5], it may be considered
a marker of severity, it may contribute to airway remodeling in asthma
[6] and it may be associated to speciﬁc asthma phenotypes [7]. In mice
cigarette smoke exposure increases IL-33 and its receptor ST2L [8] and
these events lead to increased numbers of innate immunity effector
cells such as neutrophils and macrophages within the airways.
The exposure to cigarette smoke, the major risk factor for chronic
obstructive pulmonary disease (COPD), alters innate immune responses
of thebronchial airwayepitheliumby increasingTLR4expression [9–11]
and reducing human beta defensin 2 expression (hBD2) [11]. TLR-
mediated innate signaling pathway regulates the synthesis of IL-33 in
an ocular mucosal epithelium [12]. The mechanisms regulating the
expression and the release of IL-33 in the airways of smokers are largely
unknown.
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smoke extracts (CSEs) alter the expression and/or the release of
IL-33 and to assess whether this alteration is due to an altered activa-
tion of TLR4. To this purpose, a combined ex-vivo and in vitro
approach was used for assessing IL-33 levels in mini-broncho-
alveolar lavage (mini-BAL) or IL-33 expression in bronchial
epithelium of smokers and performing experiments with bronchial
epithelial cells stimulated with CSE.
2. Materials and methods
2.1. Patient population
Non-smoking subjects (n = 7) and smoking subjects (N15 pack-
year) (n = 9) both with acute respiratory failure upon surgery for
abdominal or thoracic aneurysm were recruited at the ICU of the
Department of Anesthesiology, Reanimation and Emergency of the Uni-
versity of Palermo, Italy. Patientswith x-ray or clinical evidence of sepsis
or pneumonia at the time of mini-BAL collection were not included. All
recruited subjects required mechanical ventilation and underwent
therapy with antibiotics and systemic corticosteroids (no signiﬁcantly
different doses among the patients included in the study). Lung tissue
specimens from central bronchi from smoking (n = 5) (N15 pack-
year) and from non-smoking (n = 5) subjects were also collected
from patients who underwent surgery for lung cancer. These latter
patients were recruited at ISMETT in Palermo, Italy. The study was
approved by the Ethic Committee of Policlinico-Giaccone Hospital-
Palermo Italy (7/2012) and was in agreement with the Helsinki
Declaration. Informed written consent from either the patients or
closest relatives was obtained.
2.2. mini-BAL collection and processing
Distal lung ﬂuid samples (mini-BAL) were obtained using BAL Cath
system (by Kimberly-Clark Health Care, Kent, ME19 4HA, United
Kingdom) within 1 h from the intubation as previously described [13].
The protected catheter was blindly advanced through the endotracheal
tube until it was wedged into a distal airway and two aliquots of 10 ml
of sterile 0.9% NaCl were instilled and gently suctioned (recovered
volume about 70% of the instilled volume). Mini-BAL samples were
ﬁltered through a sterile gauze and then centrifuged at 1300 rpm for
10 min to separate cells from supernatants. The supernatants were
used for assessing IL-33 concentrations.
2.3. IL-33 concentrations
The concentrations of IL-33 (Duoset; R&D Systems, Minneapolis,
MN) (range 23.4–1500 pg/ml) were determined with enzyme-linked
immunosorbent assays (ELISA).
2.4. Immunohistochemistry
Tissue specimens from central bronchiwere selected, ﬁxedwith 10%
Neutral buffer formalin and embedded in parafﬁn wax. Three-
micrometer tissue sections were attached to poly-L-lysine coated mi-
croscope slides and, after dewaxing and rehydration, were stained
with hematoxylin and eosin (HE) or analyzed by means of immunohis-
tochemistry as previously described [14]. Immunohistochemistry and
image analysis were used to determine IL-33 expression using a
mouse monoclonal IgG antibody anti-IL-33 (Adipogen, San Diego, CA;
Clone IL33305B) (1:15; overnight) in central (internal perimeter N6
mm) airways. LSAB2 Dako kit (Code N° K0674) (Dako, Glostrup,
Denmark) and Fuchsin Substrate-Chromogen System Dako were used
for the staining. Nonimmune mouse (Dako) immunoglobulins were
used for negative controls. The immunoreactivity was evaluated blindlyby 2 independent investigators using a Leica (Wetzlar, Germany)
microscope ×400 magniﬁcation.
2.5. Preparation of cigarette smoke extracts (CSEs)
Commercial cigarettes (Marlboro) were used in this study. Cigarette
smoke solutionwas prepared as described previously [9]. Each cigarette
was smoked for 5 min and one cigarette was used per 10 ml of PBS to
generate a CSE-PBS solution. The CSE solution was ﬁltered through a
0.22 μm-pore ﬁlter to remove bacteria and large particles. The smoke
solution was then adjusted to pH 7.4 and used within 30 min of prepa-
ration. This solution was considered to be 100% CSE and diluted to ob-
tain the desired concentration in each experiment. The concentration
of CSE was calculated spectrophotometrically measuring the OD as
previously described [15] at a wavelength of 320 nm. The pattern of
absorbance, among different batches, showed very little differences
and themeanOD of the different batcheswas 1.37± 0.16. The presence
of contaminating LPS on undiluted CSE was assessed by a commercially
available kit (Cambrex Corporation, East Rutherfort, New Jersey, USA)
and was below the detection limit of 0.1 EU/ml.
2.6. Bronchial epithelial cell cultures
16-HBE, an immortalized normal bronchial epithelial cell line [16] or
primary normal human bronchial epithelial (NHBE) cells (ATCC —
catalog n. PCS-300-010) were used in this study. Bronchial epithelial
cells were maintained in MEM (Gibco, BRL, Germany), supplemented
with 10% fetal calf serum (Gibco). Cell culturesweremaintained in a hu-
midiﬁed atmosphere of 5% CO2 in air at 37 °C. Cells were cultured in the
presence and absence of CSE (5%, 10% and 20%) for 24 and 72 h. In some
experiments cell cultures were also stimulatedwith LPS (Sigma-Aldrich
Corporate, St Louis, MO) (1 μg/ml), with TNFα (100 ng/ml) or were in-
cubated with an inhibitor of TLR4 (CLI-095) (InvivoGen, San Diego, CA)
(1 μg/ml) 6 h before stimulation with CSE following the protocol
provided with data sheet by InvivoGen. Different time points (6, 12,
24 and 48 h) for IL-33 mRNA experiments were evaluated. At the end
of stimulation, cells, cell extracts, and cell culture supernatants were
collected for further evaluations.
2.7. Flow cytometry
The expression of IL-33 in 16-HBE cells was evaluated by ﬂow-
cytometry using a FACS Calibur (Becton Dickinson, Mountain View,
CA). To evaluate the expression of intracellular IL-33 before incubation
with mouse monoclonal antibody, cells were treated overnight with
GolgiStop (2 μM ﬁnal concentration) (BD PharMingen) and ﬁxed with
PBS containing 4% paraformaldehyde for 20 min at room temperature.
Fixed cells were washed twice in permeabilization buffer (PBS contain-
ing 1% FBS, 0.3% saponin, and 0.1% Na azide) for 5 min at 4 °C, then in-
cubated with a mouse monoclonal IgG antibody anti-IL-33 (Adipogen)
(1:100; for 1 h) followed by a FITC conjugated anti-mouse IgG
(Dako, Glostrup, Denmark). Negative controls were performed using
mouse immunoglobulin negative control (Dako). Data are expressed
as percentage of positive cells.
2.8. Immunocytochemistry
The expression of IL-33 in 16-HBE cellswas evaluated by immunocy-
tochemistry as previously described [14] using amousemonoclonal IgG
antibody anti-IL-33 (Adipogen) (1:15; overnight). LSAB2 Dako kit
(Code N° K0674) (Dako) and Fuchsin Substrate-Chromogen System
Dako were used for the staining. Nonimmune mouse (Dako) immuno-
globulins were used for negative controls. The immunoreactivity was
evaluated blindly by 2 independent investigators using a Leica (Wetzlar,
Germany) microscope ×400 magniﬁcation.
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Real time PCRwas performed as previously described [10] in 16-HBE
and inNHBE. The cellswere stimulatedwith CSE (20%) for 18 h and total
cellular RNA extracted using TriZol reagent (Invitrogen) was reverse-
transcribed to cDNA, using M-MLV-RT and oligo(dT)12–18 primer
(Invitrogen, Carlsbad, CA, USA). Real-time quantitative PCR of human
IL-33 gene was carried out on Step One Plus Real-time PCR System
(Applied Biosystems, Foster City, CA, USA) using speciﬁc FAM-labeled
probe and primers (prevalidated TaqMan Gene expression assay for
IL-33, Hs01125943m1, Assays on Demand, Applied Biosystems).
GAPDHgene expressionwas used as endogenous control for normaliza-
tion. Relative quantitation of mRNA was carried out with comparative
CT method.2.10. Western blot analysis
The expression of IL-33 was evaluated by western blot analysis as
previously described [17] using a mouse IgG monoclonal antibody
anti-IL-33 (1:2000; for 1 h) (Adipogen).Membraneswere then stripped
and incubated with goat polyclonal anti-ß-actin (Sigma). Revelation
was performed with an enhanced chemiluminescence system (GE
Healthcare, Chalfont St. Giles, UK) followed by autoradiography. Nega-
tive controls were performed without primary antibody or including
an isotype control antibody. Data are expressed as densitometric
arbitrary units by correction with the density of the bands obtained
for beta-actin. To study IL-33 nuclear translocation, the protein extracts
were treated to separate the cytoplasmic and nuclear protein fractions
by using a commercial kit “NE-PER Nuclear and Cytoplasmic Extraction
Reagents” following the manufacturer's directions (Thermo Scientiﬁc;
Waltham, MA). An amount of 40 μg of total proteins was subjected
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) on 10% gels and blotted onto nitrocellulose membranes. Mem-
branes were then stripped and incubated with rabbit polyclonal lamin
B1 antibody (#9087, Cell Signaling Technology, Danvers, MA-USA) for
assessing quality control of nuclear extracts.2.11. Statistics
Data are expressed as medians and inter-quartile range or as mean
counts ± standard deviation. A non-parametric Mann Whitney test
was applied for comparisons between the two subject groups. Compar-
ison between different experimental conditions was evaluated by
paired t test. p b 0.05 was accepted as statistically signiﬁcant.Fig. 1. IL-33 concentrations inmini-BAL (A) and in sera (B) from smokers. Mini-BAL supernatan
centrations were measured by ELISA as described in the “Materials and methods” section and a
non-smokers.3. Results
3.1. IL-33 concentrations in mini-BAL and sera from smokers
The concentrations of IL-33 in mini-BAL and sera from smokers and
from non-smokers were initially assessed. Mini-BAL (Fig. 1 A) but not
sera (Fig. 1 B) from smokers showed signiﬁcant reduced concentrations
of IL-33 when compared to non-smokers suggesting that this reduced
release of IL-33 is a phenomenon mainly compartmentalized within
the airways of smokers. No correlation was found between serum and
mini-BAL IL-33 concentrations (data not shown).
3.2. IL-33 expression by bronchial epithelium in smokers
IL-33 is mainly expressed by stromal cells including epithelial cells
[18]. The expression of IL-33was assessed in the epithelium of large air-
ways from non-smokers and from smokers. In tissue samples, IL-33 im-
munoreactivity was more evident in basal cells of bronchial epithelium
of smokers in comparison to non-smokers (Fig. 2). The immunoreactiv-
ity of IL-33 in smokers was similar to the immunoreactivity of IL-33 in
an asthmatic subject used as positive control [4,5].
3.3. Effects of CSE on IL-33 release by bronchial epithelial cells
To clarify whether cigarette smoke alters the release of IL-33, the
in vitro effects of CSE on IL-33 release by bronchial epithelial cells
were explored. CSE reduced IL-33 release by bronchial epithelial cells
in a dose dependent manner (Fig. 3).
3.4. Effects of CSE on intracellular IL-33 expression by bronchial epithelial
cells
The effect of CSE on the intracellular content of IL-33 by bronchial
epithelial cells was assessed. CSE at higher tested concentration (20%)
increased intracellular IL-33 expression in bronchial epithelial cells at
both tested time points. The expression of IL-33 was more relevant
after 24 (Fig. 4A) than after 72 h (Fig. 5). The increased expression of
IL-33 after 24 h of CSE exposure was conﬁrmed also by immunocyto-
chemistry (Fig. 4B). The immunolocalization of IL-33 is prevalent in
the cell cytoplasm (see the higher magniﬁcation of Fig. 4B).
3.5. Effects of CSE on full length ormature IL-33 expression by bronchial ep-
ithelial cells
Further experiments were designed to clarify whether the increase
of intracellular IL-33 was referred to the increase of the full-length IL-ts were recovered from non-smoker (n= 7) and from smoker (n=9) subjects. IL-33 con-
re expressed as pg/ml. Data are expressed as median and inter-quartile range. *p b 0.05 vs
Fig. 2. IL-33 expression bybronchial epithelium in smokers. Immunohistochemistry for IL-33 in large airways from surgical samples of non-smokers (Controls) (n=2), of smokers (n=2)
and of an asthmatic subject was performed. IL-33 immunostaining (red stain) at 400× magniﬁcation is shown. Arrows indicate IL-33 immunostaining.
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Full length IL-33 was increased in the cytoplasm but not in the nucleus
of CSE stimulated bronchial epithelial cells (Fig. 6).
3.6. Effects of CSE on IL-33 mRNA expression by bronchial epithelial cells
We next assessed whether the increased expression of IL-33 due to
cigarette smoke exposure was due to increased gene expression. CSE
increased IL-33 mRNA expression in 16HBE (Fig. 7A) and in primary
bronchial epithelial cells (Fig. 7B).
3.7. Effect of TLR4 on IL-33 mRNA and protein expression by bronchial
epithelial cells
Cigarette smoke alters the activation of Toll like receptors [8–10].
Since the role of Toll like receptor activation on IL-33 expression is con-
troversial [19,20], the effects of TLR4 related events on the expression ofFig. 3. Effects of CSE on IL-33 release by bronchial epithelial cells. Bronchial epithelial cells
(16-HBE, n = 5) were cultured in the presence and in the absence of CSE (10% and 20%)
for 24 h. The supernatants were collected and used for evaluating IL-33 concentrations
by ELISA. Results are expressed as mean ± SD. *p b 0.05.IL-33were explored. In particular, for IL-33mRNAexpression,we tested
different time points, different CSE concentrations, an agonist (LPS) and
an antagonist (CLI-095) of TLR4, and included, as a positive control,
TNFα [5]. IL-33 mRNA expression increased upon CSE exposure in a
time and in a dose dependent manner (Fig. 8). TNFα increased, LPS re-
duced while TLR4 inhibition increased IL-33mRNA in bronchial epithe-
lial cells. The combined exposure of bronchial epithelial cells to LPS and
CSE increased the expression of IL-33mRNA in comparison to LPS alone
(Fig. 8).
In terms of protein expression, the agonist of TLR4, LPS, reduced
while TLR4 inhibition increased total intracellular IL-33 in bronchial ep-
ithelial cells (Fig. 9). TLR4 inhibition increased the full length IL-33 form
expression in bronchial epithelial cells (Fig. 10).
3.8. Effect of TLR4 on IL-33 release by bronchial epithelial cells
Finally, the effects of TLR4 on IL-33 release by bronchial epithelial
cellswere explored. TNFα increasedwhile CSE 20% andCLI-095 reduced
IL-33 release by bronchial epithelial cells. LPS alonedid not have any sig-
niﬁcant effects on IL-33 release. The combined exposure of LPS and CSE
increased the release of IL-33 in comparison to CSE alone (Fig. 11).
4. Discussion
Cigarette smoke is a profound pro-inﬂammatory stimulus and is the
principal cause of chronic obstructive pulmonary disease (COPD), a dis-
order characterized by airway inﬂammation and bronchial obstruction.
IL-33 is a cytokine belonging to IL-1 family (IL-1α, IL-1β, IL-18) with
a dual function, acting both as a traditional cytokine through activation
of the ST2L receptor complex and as an intracellular nuclear factor with
transcriptional regulatory properties. As epithelial cells are the ﬁrst line
of defense against foreign noxae, the response of normal epithelial cells
to smoke has been extensively studied. The present study demonstrates
for the ﬁrst time that in smokers IL-33 levels are reduced within the
lumen of the airways and that IL-33 expression is increased within the
bronchial epithelium. Cigarette smoke is responsible for the reduced
IL-33 release as well as for the intracellular cytoplasmic accumulation
of the full length forms of IL-33 in bronchial epithelial cells. The role of
Fig. 4. Effects of CSE on intracellular IL-33 expression by bronchial epithelial cells (24 h). Bronchial epithelial cells (16-HBE, n = 5) were cultured in the presence and in the absence of
different concentrations of CSE (5%, 10% and 20%) for 24 h. A. The intracellular expression of IL-33 was assessed by ﬂow-cytometry and the results are expressed as percentage of positive
cells (mean± SD). *p b 0.05 vs baseline. Representative dot plots are shown. B. 16-HBEwere cultured in the presence and in the absence of CSE 20% and IL-33 expressionwas assessed by
immunocytochemistry. Representative images of IL-33 expression from 3 experiments are shown.
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is also described.
IL-33 is mainly expressed by stromal cells, such as epithelial and en-
dothelial cells, and has been suggested to act as an “alarmin” orchestrat-
ing protective antiviral cytotoxic T lymphocyte responses [21] or
increasing the activity of the innate type 2 lymphoid cells. These latter
cells are involved in the initiation of the type 2 immune response (secre-
tion of IL-5 and IL-13) during parasitic infection and allergic diseases
such as bronchial asthma [18]. IL-33 mRNA and protein as well as
IL-33 lumen secretion are all increasedwithin the airways of asthmatics
[4,5] suggesting that bronchial epithelium and other airway residentFig. 5. Effects of CSE on intracellular IL-33 expression by bronchial epithelial cells (72 h). Bron
different concentrations of CSE (5%, 10% and 20%) for 72 h. The intracellular expression of IL-3
cells (mean ± SD). *p b 0.05 vs baseline. B. Representative dot plots are shown.cells express elevated levels of IL-33 in asthma and may also be
subjected to conditions favoring its release.
In the present study IL-33 levels are signiﬁcantly reducedwithin the
lumen of the airways but not in sera of smokers suggesting that speciﬁc
signals present in the lung compartment are responsible for the reduced
release of this alarmin, a signal crucial to alert the host innate immune
system.
Differently, IL-33 immunoreactivity is more evident in basal cells of
bronchial epithelium of smokers in comparison to non-smokers. A
more accurate estimation of the differences between smokers and
non-smokers could be provided by analysing a greater number ofchial epithelial cells (16-HBE, n = 5) were cultured in the presence and in the absence of
3 was assessed by ﬂow-cytometry. A. The results are expressed as percentage of positive
Fig. 6. Effects of CSE on full length IL-33 expression by bronchial epithelial cells. Bronchial
epithelial cells (16-HBE, n = 3) were cultured in the presence and in the absence of CSE
20% for 24 h. A. Cytoplasmic and nuclear proteins were extracted and the full length
expression of IL-33 was assessed by western blot analysis using a mouse IgG monoclonal
antibody anti-IL-33. Membranes were then stripped and incubated with goat polyclonal
anti-ß-actin and with rabbit polyclonal anti-lamin B1. Representative western blots are
shown (NT=not treated/baseline). B. Signals corresponding to cytoplasmic IL-33 expres-
sion on the variouswestern blotswere semiquantiﬁedbydensitometric scanning, normal-
ized, and expressed after correction with the density of the band obtained for beta-actin.
Data are expressed as arbitrary units ± SD. *p b 0.05 vs baseline.
Fig. 8. Effects of different CSE concentrations and of TLR4 on IL-33 mRNA expression by
bronchial epithelial cells. Bronchial epithelial cells (16-HBE)were cultured in the presence
and in the absence of CSE (5%, 10% and 20%), of LPS (1 μg/ml), of an inhibitor of TLR4
(CLI-095) and of TNFα (100 ng/ml) for 6, 12, 24 and 48 h. Total RNA was extracted and
real time PCR was used to assess IL-33 gene expression. GAPDH gene expression was
used as endogenous control for normalization. Relative quantitation of mRNAwas carried
out with comparative CT method. Results are reported as relative unit and normalized to
non-treated control (baseline).
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in vitro experiments with CSE stimulated bronchial epithelial cells
were designed. Cigarette smoke in bronchial epithelial cells reduced
IL-33 release while it increased the IL-33 mRNA as well as the intracel-
lular content of the full length form of Il-33. IL-33 may be released to
effect paracrine signaling not only exclusively during cellular necrosis,
as initially thought, but also by membrane-bound cytoplasmic vesicles
during biomechanical overload [22]. The impairment in the release of
IL-33 may be linked to the ﬁnding that IL-33 mRNA could be translated
without a signal sequence for secretion [23]. It is conceivable that CSE in
bronchial epithelial cells could induce this IL-33 mRNA without signal
sequence for secretion and further experiments are needed to clarify
this point. Alternatively CSE might induce post-transcriptional alter-
ations on IL-33 that in turn lead to the reduced secretion. Furthermore,
in the present study CSE did not increase the nuclear translocation ofFig. 7. Effects of CSE on IL-33 mRNA expression by bronchial epithelial cells. Bronchial epitheli
(B) were cultured in the presence and in the absence of CSE 20% for 18 h. Total RNA was extra
was used as endogenous control for normalization. Relative quantitation of mRNA was carried
non-treated control (baseline). Data are expressed as mean ± SD. *p b 0.05 vs baseline.IL-33 in bronchial epithelial cells. Taken together these ﬁndings suggest
that CSE may promote the accumulation of full length IL-33 within the
cytoplasm of bronchial epithelial cells via multiple mechanisms: 1) in-
creasing IL-33 gene expression and 2) negatively interfering with the
extracellular release, and 3) not promoting the nuclear translocation.
IL-33 may be present in a full length and in a mature form. Unlike
IL-1β and IL-18, full-length IL-33 is biologically active independently
of caspase-1 cleavage [24] and processing by caspases results in IL-33
inactivation [25]. In our model, also at higher cigarette smoke concen-
tration (20%) we did not observe any signiﬁcant caspase-3 activation
(data not shown). Neutrophil serine proteases, cathepsin G and elastase
can cleave full-length human IL-33 and generate mature forms IL-33
that are biologically active and have a 10-fold higher activity than full-
length IL-33 in cellular assays [24]. Intracellular full length IL-33 was
found to possess transcriptional repressor properties [26]. Although in
mouse the two isoforms share some activities, such as lymphocyte
and neutrophil increasing inﬁltration, pulmonary eosinophilia and gob-
let cell hyperplasia are promoted by mature IL-33 [2]. IL-33 expression
increases, together with an increased inﬁltration of neutrophils and
macrophages and to increased expression of inﬂammatory markers, in
the lung tissues ofmice exposed to cigarette smoke and all these inﬂam-
matory events are reverted in cigarette smoke exposed animals by theal cells (16-HBE, n = 3) (A) and primary normal bronchial epithelial cells (NHBE, n = 3)
cted and real time PCR was used to assess IL-33 gene expression. GAPDH gene expression
out with comparative CT method. Results are reported as relative unit and normalized to
Fig. 9. Effect of TLR4 on intracellular IL-33 expression by bronchial epithelial cells. Bronchial epithelial cells (16-HBE, n=3)were cultured in the presence and in the absence of CSE 20%, of
LPS (1 μg/ml), and of an inhibitor of TLR4 (CLI-095) for 24 h. The intracellular expression of IL-33 was assessed by ﬂow-cytometry. A. The results are expressed as percentage of positive
cells (mean ± SD). *p b 0.05. B. Representative dot plots are shown.
1636 E. Pace et al. / Biochimica et Biophysica Acta 1842 (2014) 1630–1637intranasal administration of an anti-IL-33 antibody [5]. Inﬁltration of
neutrophils could be due to the release of chemokines including IL-8.
In this regard, it has been demonstrated that IL-33 mediates IL-8 pro-
duction by epithelial cells via ERK activation [27]. IL-8 up-regulation is
an event associated to cell senescence and IL-33 may be associated toFig. 10. Effects of TLR4 on full length IL-33 expression bybronchial epithelial cells. Bronchi-
al epithelial cells (16-HBE, n = 3) were cultured in the presence and in the absence of an
inhibitor of TLR4 (CLI-095) for 24h. Total proteinswere extracted and the expression of IL-
33was assessed bywestern blot analysis using a mouse IgG monoclonal antibody anti-IL-
33. Membranes were then stripped and incubated with goat polyclonal anti-ß-actin. Sig-
nals corresponding to IL-33 on the various western blots were semiquantiﬁed by densito-
metric scanning, normalized and expressed after correction with the density of the band
obtained for beta-actin. A. Data are expressed as arbitrary units± SD. *p b 0.05 vs baseline.
B. Representative western blots are shown. Lane 1 = baseline; lane 2 = CLI-095.senescence mechanisms since it increased in elderly in comparison to
young mice [28].
IL-33 acts as a transcriptional regulator of the p65 subunit of NF-κB
[29] and mediates the expression of intercellular adhesion molecule
(ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 in endothelial
cells both basally and in response to tumor necrosis factor-a-treatment
[30]. It is not knownwhether IL-33 increases adhesionmolecule expres-
sion also in airway epithelial cells.
IL-33 is a marker of endothelial cell quiescence, is coexpressed with
the cyclin-dependent kinase inhibitor p27(Kip1) [31], and is induced by
Notch 1 [3]. Notch 1 signiﬁcantly suppresses TLR4 mediated inﬂamma-
tory responses in macrophages [32]. In smokers with or without COPD
although TLR4 expression is increased, the activation of this receptor
is altered [10]. Indeed, the exposure of CSE in bronchial epithelial cells
blocks the induction of HBD2 mRNA generated by exposure to IL-1
beta [10] and negatively interferes with the LPS-induced activation of
NFkB pathway [8,9]. In the present study a crucial role of TLR4 in theFig. 11. Effects of TLR4 on IL-33 release by bronchial epithelial cells. Bronchial epithelial
cells (16-HBE, n = 5) were cultured in the presence and in the absence of CSE (20%), of
LPS (1 μg/ml), of an inhibitor of TLR4 (CLI-095), and of TNFα (100 ng/ml) for 24 h. The
supernatants were collected and used for evaluating IL-33 concentrations by ELISA.
Results are expressed mean ± SD. *p b 0.05.
1637E. Pace et al. / Biochimica et Biophysica Acta 1842 (2014) 1630–1637expression and release of IL-33 was demonstrated since: 1) the release
of IL-33was increased inhibiting TLR4; 2) LPS reduced and a TLR4 inhib-
itor increased both the IL-33 mRNA and constitutive full length form of
IL-33. A previous paper demonstrates that IL-33 in bronchial epithelial
cells may be induced by IFNγ but not by LPS [19]. On the other hand,
LPS induces IL-33mRNA inmurinemacrophages [19] and IL-33 can sig-
niﬁcantly contribute to reduce innate immunity responses in skin since
it decreases the expression of hBD2 in acute eczematous reaction [33].
Furthermore, since CSE may contain LPS, in our experimental model
the addition of the LPS alone to bronchial epithelial cells represents an
internal control to discriminate the effect of LPS and of CSE extracts.
Taken together these ﬁndings support the concept that within the
airways of smokers a defective TLR4 activation could lead to increased
IL-33 levels in bronchial epithelial cells and further support previous
published data on asthma showing an association between IL-33 and
toll like receptor pathway molecules [7].
In conclusions, in bronchial epithelial cells the expression and the re-
lease of IL-33 are tightly controlled. Cigarette smoke,within the airways,
altering the innate immune responses could promote the accumulation
of IL-33 in bronchial epithelial cells. Further studies aimed to clarify
the functional consequences of the increased expression of IL-33 in
cigarette smoke stimulated cells are needed.
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